Evidence map›Paper›PMID 40223917›Full record

ReviewPsychopharmacology bulletin2025

Quetiapine and Paediatric Psychiatrica:

Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Psychopharmacology bulletin, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ahmed NaguyNaguy, MBBch, MSc, MRCPsych (UK), Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.
Saxby PridmorePridmore, MD, FRANZCP, Discipline of Psychiatry, University of Tasmania, Hobart, Tasmania, Australia and TMS Unit, Saint Helens Private Hospital, Hobart, Tasmania.
Hend Fm Fr AleneziAlenezi, MD, General Adult Psychiatry Department, Kuwait Centre for Mental Health (KCMH), Kuwait.
Bibi AlamiriAlamiri, MD, ABPN, ScD, Al-Manara CAP Centre, Kuwait Centre for Mental Health (KCMH), Shuwaikh, State of Kuwait.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.

Indexed as

Antipsychotic AgentsBipolar DisorderQuetiapine FumarateSchizophreniaAdolescentChildHumansAntipsychotic AgentsQuetiapine Fumaratebipolardeliriumdisruptive behavioursinsomniapediatricquetiapineschizophrenia

Identifiers

PMID40223917
PMCPMC11983474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.